Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • CA-125 Antigen
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Preoperative Care
  • Tomography, X-Ray Computed

abstract

  • Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED). None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity and no cardiac toxicity was evident. Seventy-nine percent (11 of 14) of patients experienced grade III or IV neutropenia. In summary, LED did not show antitumor activity in the treatment of advanced renal cell carcinoma.

publication date

  • December 1994

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/BF00873048

PubMed ID

  • 7775134

Additional Document Info

start page

  • 323

end page

  • 5

volume

  • 12

number

  • 4